IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in IO Biotech, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q3 2023
- Shares held
- 29.4M
- −267.9K (−0.9%) vs. Q3 2023
- Total value
- $55.3M
- +$13.6M (+32.5%) vs. Q3 2023
- New holders
- 3
- 4 more added
- Sold out
- 4
- 4 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 6,173,439 | $11.6M | 0.95% | 00.0% | Unchanged |
| Novo Holdings A/S | 5,747,067 | $10.8M | 0.72% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 3,640,015 | $6.84M | 1.06% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 2,341,107 | $4.40M | 0.26% | +987,654+73.0% | Added |
| Morgan Stanley | 2,281,682 | $4.29M | 0.00% | +2,212,869+3,215.8% | Added |
| Marshall Wace, LLP | 2,105,262 | $3.96M | 0.01% | 00.0% | Unchanged |
| Armistice Capital, LLC | 1,924,000 | $3.62M | 0.10% | −224,000−10.4% | Reduced |
| Bank of America Corp | 1,844,185 | $3.47M | 0.00% | −10,000−0.5% | Reduced |
| Stonepine Capital Management, LLC | 1,666,037 | $3.13M | 1.35% | −309,271−15.7% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.62M | 0.41% | 00.0% | Unchanged |
| Logos Global Management LP | 493,827 | $928.4K | 0.10% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 145,200 | $273.0K | 0.01% | +13,000+9.8% | Added |
| Renaissance Technologies LLC | 88,900 | $167.0K | 0.00% | +64,514+264.6% | Added |
| Citadel Advisors LLC | 51,867 | $97.5K | 0.00% | +51,867 | New |
| Geode Capital Management, LLC | 12,730 | $23.9K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 11,204 | $21.1K | 0.00% | +11,204 | New |
| Wealth Enhancement Advisory Services, LLC | 10,000 | $18.8K | 0.00% | −100−1.0% | Reduced |
| Comerica Bank | 2 | $4 | 0.00% | +2 | New |
| Avoro Capital Advisors LLC | 0 | $0 | 0.00% | −2,055,883−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −987,654−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −21,238−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −908−100.0% | Sold out |